Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients With Mild to Moderate Alzheimer's Disease

Authors not listed

Memory Pharmaceuticals · 2005

Dysbiosis Human Randomized controlled trial

Abstract

The purpose of this study is to determine in a 12-week treatment study if MEM 1003 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-26 MST

Cite this

APA

Anonymous. (2005). A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients With Mild to Moderate Alzheimer's Disease. <em>Memory Pharmaceuticals</em>. https://clinicaltrials.gov/study/NCT00257673

Vancouver

Anonymous. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients With Mild to Moderate Alzheimer's Disease. Memory Pharmaceuticals. 2005.

BibTeX

@misc{anon2005AMulti, title = {A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients With Mild to Moderate Alzheimer's Disease}, author = {Anonymous}, journal = {Memory Pharmaceuticals}, year = {2005}, }